Omeros to Discontinue Narsoplimab Trial After Early Data Didn’t Meet Primary Endpoint

• Omeros is discontinuing its clinical trial for narsoplimab in the treatment of immunoglobulin A nephropathy.
• Interim data from the trial did not meet the primary endpoint.
• Narsoplimab did not show statistically significant improvement over placebo.
• Omeros will not seek approval for narsoplimab in this indication.
• Further analysis of the data will be conducted to understand the trial results and identify biomarkers.
• Funds originally allocated for the trial will be redirected.

Omeros has decided to discontinue its late-stage clinical trial for narsoplimab, a drug being evaluated for the treatment of immunoglobulin A nephropathy. The interim data from the trial did not meet the primary endpoint, showing that narsoplimab did not achieve statistically significant improvement over placebo. As a result, Omeros will not be submitting an application for approval of narsoplimab in this indication. The company plans to conduct further analysis of the data to better understand the trial results and identify any useful biomarkers. The funds originally allocated for the continuation of the trial will now be redirected.